Researchers used a second-generation pro-drug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given the newly developed prodrug. This mitochondrial-targeted prodrug also greatly improves outcomes when coupled with standard therapies of radiation and/or chemotherapy.